Xaira Therapeutics
Foundation-model-driven pipeline built on generative protein design and perturbation data.
Full Xaira Therapeutics record →Head to head
Xaira Therapeutics vs Boltz
Xaira Therapeutics (Xaira Therapeutics) and Boltz (MIT) both sit in Science & Bio. Xaira Therapeutics shipped more tracked changes in the last 30 days (7 vs 5). Every value below comes from the latest crawl of the vendors' own pages.
| Attribute | Xaira Therapeutics Xaira Therapeutics | Boltz MIT |
|---|---|---|
| Segment | Science & Bio | Science & Bio |
| Version | Xaira Platform | Boltz-2 |
| Entry cost | Pricing is not publicly disclosed (Enterprise/Drug Discovery Platform) | Pricing is not published. API and Enterprise deployments available. |
| Pricing tiers | — | — |
| Model stack | Proprietary · X-Atlas/Pisces · X-Automate · X-Cell · X-Design · X-Patient · X-Scientist | Boltz-2 · BoltzGen · BoltzMol-1 · BoltzProt-1 |
| Context window | — | — |
| Public API | ||
| Routes models | ||
| Changes / 30d | 7 | 5 |
| Origin | United States | United States |
| Capabilities | Generative protein design, Perturbation atlases, Wet-lab loop, predictive AI models, agentic AI models, virtual cells, drug discovery, AI models for drug discovery | Open weights, Affinity prediction, Complex structures, Local inference, Design small molecules, Design proteins, Predict structures, Fine-tuning |
Boltz
Open-source, AlphaFold3-class biomolecular structure and affinity prediction.
Full Boltz record →